#United States #New York #Levi & Korsinsky #Lawsuit #Aardvark Therapeutics

Aardvark Therapeutics Investor Alert

Aardvark Therapeutics, Inc. (NASDAQ: AARD) is currently facing a securities class action lawsuit brought by Levi & Korsinsky, LLP, concerning the alleged misstatements regarding the safety and efficacy of their drug, ARD-101. The lawsuit specifically targets investors who acquired stocks between February 13, 2025, and May 14, 2026, including those who participated in the company’s initial public offering (IPO) held in February 2025.

Background of Allegations

During the IPO, Aardvark touted ARD-101 as a "99% gut-restricted" treatment with minimal systemic absorption, claiming that the drug had shown no serious adverse events (SAEs) in clinical trials. However, reality took a different turn when, on February 27, 2026, Aardvark announced a voluntary pause in their Phase 3 HERO trial. This was due to significant findings related to cardiac observations during routine safety monitoring, raising concerns about the drug’s safety profile. Shortly after, on May 14, 2026, the FDA imposed a full clinical hold on the clinical trials of ARD-101.

The abrupt halt to the HERO trial, compounded by the announcement of cardiac complications, triggered a substantial drop in share prices. From an IPO price of $16.00 per share, stocks plummeted to $4.57, representing a staggering decline of 71.4%. Investors are now seeking justice for their losses, and the deadline for lead plaintiff applications is set for October 13, 2026.

Detailed Breakdown of Misleading Claims

1. Promised Safety: Aardvark claimed that ARD-101 had no serious adverse events. However, the cardiac observations that led to the trial's suspension contradicted these assurances.

2. Data Timeline: The company projected topline Phase 3 data to be available in early 2026. This expectation has now been pushed back indefinitely, raising red flags for investors anticipating results.

3. FDA Interaction: Aardvark asserted that their clinical strategy was aligned with the FDA's expectations, which turned out to be far from the truth, as evident from the subsequent clinical hold imposed by the agency.

These discrepancies emphasize the importance of transparent communication from companies, especially in the high-stakes biotechnology industry.

Action Steps for Investors

For those who invested in Aardvark during the designated class period, it's essential to gather evidence such as brokerage records that detail purchase dates, quantities, and prices paid. This documentation will support claims for recovery. Levi & Korsinsky is currently evaluating cases to assist investors in assessing potential recoveries.

Regardless of whether investors still hold their shares, those who purchased during the class period may still be eligible to recover losses. Notably, participation in the lawsuit incurs no upfront costs, as legal representation is often contingent on outcomes, typically subject to court approval.

Potential class members are encouraged to connect with Joseph E. Levi, Esq. for a comprehensive review of their situation. As a firm recognized for its advocacy and track record in protecting shareholder rights, Levi & Korsinsky is committed to helping investors navigate the complex landscape following these serious allegations.

In conclusion, as the trial progresses, investors must remain vigilant and proactive to secure their rights, especially in cases where they feel misled regarding a company's assurances on product efficacy and safety. Aardvark’s current predicament serves as a crucial reminder of the responsibilities companies have toward their investors, highlighting the fine line between market optimism and transparency in the communications regarding clinical results. Investors may reach out at (212) 363-7500 for more information or to discuss potential recovery options.